Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
SAN DIEGO, CA / / September 15, 2026 / Ensysce Biosciences, Inc. NASDAQ:ENSC ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), hosted…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.